The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Self-collection devices designed for ease of use and safety
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The segment delivered strong sales growth of 20% YoY
Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Subscribe To Our Newsletter & Stay Updated
